BackBeam Therapeutics Overview

Beam Therapeutics Net Income

Track Beam Therapeutics's net income ($-85M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$122.68M
↓ 19.93% YoY

As of Jun 2026

Annual Net Income (TTM)

-$85.43M
↑ 78.57% YoY

Trailing 12 months ending Jun 2026

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Beam Therapeutics (BEAM) FAQ

Beam Therapeutics (BEAM) currently reports a net income of $-85M as of June 2026. That compares with $-400M in the prior-year period — up 78.6% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Beam Therapeutics's net income history and peer comparisons.

Beam Therapeutics's net income increased from $-400M to $-85M — a 78.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Beam Therapeutics's net income of $-85M is lower than the Healthcare sector average of $16B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Beam Therapeutics reported $-85M in net income as of June 2026. That compares with $-400M in the prior-year period — up 78.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-85M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Beam Therapeutics, and consider following BEAM for alerts when major investors trade the stock.